The price of Acelyrin Inc (NASDAQ:SLRN) shares last traded on Wall Street fell -1.51% to $4.57.
SLRN stock price is now -15.28% away from the 50-day moving average and -16.76% away from the 200-day moving average. The market capitalization of the company currently stands at $458.49M.
With the price target reduced from $18 to $6, H.C. Wainwright Downgraded its rating from Buy to Neutral for Acelyrin Inc (NASDAQ: SLRN). On July 08, 2024, Wells Fargo Upgraded its previous ‘Equal Weight’ rating to ‘Overweight’ on the stock keeping its target price maintained at $13, while ‘Citigroup’ rates the stock as ‘Neutral’
In other news, Becker Daniel J., Director sold 1 shares of the company’s stock on Jul 17 ’24. The stock was sold for $7 at an average price of $6.86. Upon completion of the transaction, the Director now directly owns 2,999 shares in the company, valued at $13705.43. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 01 ’24, Chief Executive Officer Lin Shao-Lee sold 9,961 shares of the business’s stock. A total of $66,024 was realized by selling the stock at an average price of $6.63. This leaves the insider owning 1,577,374 shares of the company worth $7.21 million. A total of 27.21% of the company’s stock is owned by insiders.
During the past 12 months, Acelyrin Inc has had a low of $3.36 and a high of $8.89. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 7.15, and a quick ratio of 7.15. The fifty day moving average price for SLRN is $5.395 and a two-hundred day moving average price translates $5.505125 for the stock.
The latest earnings results from Acelyrin Inc (NASDAQ: SLRN) was released for 2024-09-30.
